Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services, and Olon S.p.A. have entered into a strategic partnership to deliver large-scale drug substance manufacturing services to pharmaceutical and biotechnology clients, leveraging Aji Bio-Pharma’s microbial CORYNEX peptide and protein manufacturing platform and Olon’s large-scale microbial fermentation capabilities.

This collaboration combines Aji Bio-Pharma’s expertise in microbial strain and process development with Olon’s large-scale GMP manufacturing expertise utilizing fermenters with a capacity of over 100,000 liters. The partnership will accelerate productive and sustainable manufacturing of high-demand proteins and peptides such as GLP-1 analogs which play a critical role in treating obesity and Type II diabetes.

“By joining forces, we can accelerate the development and supply of advanced peptides and proteins, supporting our customers and improving patient outcomes in a sustainable manner,” said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc.

Andrea Conforto, S&M – VP CDMO Biotech, Olon S.p.A., added, “Together, we provide a seamless path from development to large-scale commercial manufacturing, setting new standards for quality and sustainability in the industry.”